DataMEDS AI — Third Quarter 2026 Earnings Summary

DataMEDS AI reported a 50% sequential revenue increase to $2.7 million for the third quarter of 2026, driven primarily by growth in its Corexa Pharmacy drug dispensing operations. The company achieved a net profit of $10.535 million, resulting in a net profit per share of $2.72, a significant turnaround from the net loss recorded in the same period the previous year. Key business developments included the launch of the Health Lives Here mobile app, an exclusive license for the REBOOT GLP-1 patient management platform, and the acquisition of Helomics cancer diagnostics laboratory. Additionally, the company regained full compliance with Nasdaq listing standards and secured a memorandum of understanding with an HMO to deploy its mobile application to over 25,000 members.